{"id":3099,"date":"2025-04-15T07:03:05","date_gmt":"2025-04-15T07:03:05","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/04\/15\/2504-09157\/"},"modified":"2025-04-15T07:03:05","modified_gmt":"2025-04-15T07:03:05","slug":"2504-09157","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/04\/15\/2504-09157\/","title":{"rendered":"Dose-finding design based on level set estimation in phase I cancer clinical trials"},"content":{"rendered":"<p>    Dose-finding design based on level set estimation in phase I cancer clinical trials<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>arXiv:2504.09157v1 Announce Type: new<br \/>\nAbstract: The primary objective of phase I cancer clinical trials is to evaluate the safety of a new experimental treatment and to find the maximum tolerated dose (MTD). We show that the MTD estimation problem can be regarded as a level set estimation (LSE) problem whose objective is to determine the regions where an unknown function value is above or below a given threshold. Then, we propose a novel dose-finding design in the framework of LSE. The proposed design determines the next dose on the basis of an acquisition function incorporating uncertainty in the posterior distribution of the dose-toxicity curve as well as overdose control. Simulation experiments show that the proposed LSE design achieves a higher accuracy in estimating the MTD and involves a lower risk of overdosing allocation compared to existing designs, thereby indicating that it provides an effective methodology for phase I cancer clinical trial design.<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Keiichiro Seno, Kota Matsui, Shogo Iwazaki, Yu Inatsu, Shion Takeno, Shigeyuki Matsui<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/arxiv.org\/abs\/2504.09157\">Go to original source<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dose-finding design based on level set estimation in phase I cancer clinical trials arXiv:2504.09157v1 Announce Type: new Abstract: The primary objective of phase I cancer clinical trials is to evaluate the safety of a new experimental treatment and to find the maximum tolerated dose (MTD). We show that the MTD estimation problem can be regarded [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[62,113,112],"tags":[147,2377,374],"class_list":["post-3099","post","type-post","status-publish","format-standard","hentry","category-aimldsaimlds","category-cs-lg","category-stat-ml","tag-design","tag-dose","tag-estimation"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/3099"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=3099"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/3099\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=3099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=3099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=3099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}